CSPC Pharmaceutical : VOLUNTARY ANNOUNCEMENT - ONCOLOGY DRUG "SYHA1815 TABLETS" OBTAINS CLINICAL TRIAL APPROVAL

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CSPC Pharmaceutical Group Limited

石 藥 集 團 有 限 公 司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

ONCOLOGY DRUG "SYHA1815 TABLETS"

OBTAINS CLINICAL TRIAL APPROVAL

The board of directors (the "Board") of CSPC Pharmaceutical Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that "SYHA1815 Tablets" (the "Product") developed by Shanghai Runshi Pharmaceutical Technology Co., Ltd* ("Shanghai Runshi"), a subsidiary of the Company, has obtained approval granted by the National Medical Products Administration of the People's Republic of China to conduct clinical trials in China.

The Product is a multi-target inhibitor jointly developed by Shanghai Institute of Materia Medica under Chinese Academy of Sciences and Shanghai Runshi. The clinical indication for this approval is unresectable locally advanced or metastatic solid tumors, which include thyroid cancer, non-small cell lung cancer, gastric cancer (gastroesophageal junction cancer), colorectal cancer, pancreatic cancer and soft tissue sarcoma. The pre-clinical studies have shown that the Product has good efficacy on a number of tumors (including thyroid cancer, non-small cell lung cancer and gastric cancer) by inhibiting a variety of kinases with its high activity, and also has good safety as well as pharmacokinetic characteristics, providing a promising prospect of demonstrating good efficacy in the clinical trials.

The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.

- 1 -

By order of the Board

CSPC Pharmaceutical Group Limited

Cai Dongchen

Chairman

Hong Kong, 24 August 2020

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.

• For identification purpose only

- 2 -